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Purpose: Cardiac [123I]metaiodobenzylguanidine scintigraphy (123I-MIBG), reflecting
postganglionic cardiac autonomic denervation, is proposed for early detection of
Parkinson’s disease (PD; reduced tracer uptake) and separation from Multiple System
Atrophy (MSA; preserved tracer uptake). However, several recent studies report on
frequent unexpected 123I-MIBG results in PD and MSA. We sought to determine,
whether 123I-MIBG is feasible to discriminate PD from MSA in unselected geriatric
patients in clinical practice.
Materials and Methods: We screened consecutive patients, that underwent
123I-MIBG for diagnostic reasons. Delayed 123I-MIBG uptake (heart/mediastinum ratio;
H/M ratio) was verified by clinical diagnosis of PD, MSA, and ET based on a two-stage
clinical assessment: comprehensive baseline (including autonomic testing and additional
neuroimaging) and confirmatory clinical follow-up.
Results: 28 patients with clinical diagnosis of PD (N = 11), MSA (N = 9), and
Essential Tremor (ET, N = 8) were identified. In one third (9/28) nuclear medical diagnosis
deviated from clinically suspected syndrome. Visual interpretation of 123I-MIBG identified
two cases (MSA and ET) with indeed normal 123I-MIBG uptake. Detailed review of
clinical phenotypes provided only in two cases (PD and ET) an adequate explanation
(correction of initial diagnosis and confounding drug history) for unexpected 123I-MIBG.
In conclusion, 123I-MIBG did not match initial clinical phenotype in 27% PD, 44% MSA,
and 25% ET patients.
Conclusion: 123I-MIBG scintigraphy is a known specific and valuable technique
in scientific approaches and well-defined and highly selected samples. However,
predictability of 123I-MIBG based nuclear medical diagnosis for individual cases and
thus, feasibility in routine clinical practice is limited. Our clinical series emphasize clinical
verification of 123I-MIBG results on an individual basis in clinical routine.
Keywords: Parkinson‘s disease, Lewy body disorders, multiple system atrophy, MIBG scintigraphy, autonomic
function
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INTRODUCTION
Parkinson’s Disease (PD) and Multiple System Atrophy (MSA)
are pathophysiological distinct disorders, that share a common
clinical phenomenology. When compared to PD, MSA is
characterized by a more rapid deterioration and limited clinical
response to levodopa substitution. Despite the use of clinical
consensus criteria (1, 2) discrimination of MSA and PD,
especially at early stages, is challenging as neuropathological
confirmed case series indicate (3).
Cardiac 123I-metaiodobenzylguanidine (123I-MIBG)
scintigraphy is used to discriminate PD and MSA by means of
cardiac postganglionic autonomic involvement (4–6). Cardiac
uptake of the synthetic norepinephrine analog (123I-MIBG)
depends on integrity of postganglionic sympathetic neurons.
Since α-synuclein dependent neurodegeneration in PD affects
both pre- and postganglionic autonomic neurons, cardiac 123I-
MIBG uptake is impaired, whereas in MSA, with predominately
preganglionic autonomic failure, cardiac 123I-MIBG uptake is
thought to be preserved. Braune et al. (6) reported on 100%
sensitivity and specificity of cardiac 123I-MIBG scintigraphy
in differentiating PD and MSA, respectively. Recent clinical
studies confirmed the high sensitivity and report on specificity
more than 77% (7, 8). As such, 123I-MIBG scintigraphy
is recommended (level A) by the European Federation of
Neurological Societies and the Movement Disorder Society task
force (9) for the differential diagnosis of Parkinson syndromes.
However, there is an increasing number of reports on
impaired cardiac autonomic innervation in non-idiopathic
Parkinson such as MSA. In a longitudinal study, Nagayama et al.
(10) report consistently on a high sensitivity (87.7%) of cardiac
123I-MIBG scintigraphy in PD, but 179 of 269 patients (66.5%)
with non-Lewy body pathology showed a diminished cardiac
123I-MIBG uptake as well, resulting in a low specificity of 37.4%.
In recent studies up to 30% ofMSA patients present with reduced
cardiac 123I-MIBG uptake (10–12) and in one study (13) H/M
ratio was diminished in even 7 out of 9 MSA patients.
These unexpected 123I-MIBG results in MSA can be
attributed in part to known confounders of 123I-MIBG uptake
such asmyocardial lesions, cardiomyopathy, chronic heart failure
or peripheral neuropathy, and concomitant medication (14).
In MSA, a transsynaptic neurodegeneration causing secondary
postganglionic neuronal decline is further postulated (11).
In contrast to prospective trials of highly selected samples,
we report on our experience of 123I-MIBG performance in
a non-selected clinical sample of patients suffering various
neurodegenerative Parkinson’s syndromes. We therefore verified
the nuclear medical based classification of MSA, ET, and PD by
combining the diagnostic value of additional neuroimaging [e.g.,
123I-2β-carbomethoxy-3β-(4-iodophenyl)-N-(3-fluoropropyl)
nortropane single photon emission computed tomography
(123I-FP-CIT SPECT)], levodopa responsiveness, autonomic
function tests and a two-stage clinical assessment covering
a mean follow-up of 3 years. In this clinical series we
sought to highlight potential pitfalls of cardiac 123I-MIBG
imaging in routine clinical use and to discuss overestimated
clinical implications.
PATIENTS AND METHODS
Patients
Consecutive patients, that underwent 123I-MIBG scintigraphy
for differential diagnosis of a Parkinson syndrome within a 24-
month recruitment period at our University Medical Center,
were approached to participate in this clinical series. The study
was approved by the Institutional Review Board of Charité—
University Medicine Berlin, Germany and all patients gave
written informed consent before participation.
Clinical Assessment
Nuclear medical diagnosis derived from the results of cardiac
123I-MIBG scintigraphy (PD: reduced 123I-MIBG uptake,
MSA: preserved 123I-MIBG uptake, Essential Tremor (ET):
preserved 123I-MIBG uptake). Clinical diagnosis derived from
(1) a comprehensive clinical assessment based on consensus
diagnostic criteria (1, 2) and appropriate scales of clinical severity
[PD: UPDRS (15), MSA: UMSARS (16)], (2) standardized test
of levodopa responsiveness (UPDRS motor part before and
30min after oral administration of 200mg levodopa/50mg
benserazide), (3) autonomic reflex screen (ARS), and (4) results
of supporting imaging including transcranial mesencephalic
sonography, structural MRI, dopamine transporter SPECT
(123I-FP-CIT SPECT), and dopamine receptor SPECT (123I-
IBZM SPECT). Clinical diagnosis was further verified by a
long-term follow-up were initial diagnostic classification was
re-evaluated based on progression of motor and non-motor
symptoms, sustained levodopa responsiveness, and survival
period. If subjects were unable to present for clinical follow-up,
general practitioner or family members were contacted.
Cardiac 123I-MIBG Scintigraphy
Cardiac scintigraphy was performed according to standard
operation procedures of the Department of Nuclear Medicine,
Charité—University Medicine Berlin (17). Thyroid was blocked
by sodium perchlorate and drugs known to affect 123I-
MIBG binding, such as α-blockers, reserpine derivates, and
sympathomimetics, were stopped for least 24 h. 185 MBq 123I-
MIBG (AdreView Iobenguane (123I) Injection, GE Healthcare,
Braunschweig, Germany) was intravenously applied. Tracer
uptake was detected by double-head gamma camera equipped
with a low energy high resolution (LEHR) collimator (Millenium
VG5 Hawkeye with VPC-45K collimator; GE Medical Systems-
EU, Buc, France or Symbia TruePoint SPECT-CT; Siemens,
Erlangen, Germany). For imaging a 15% window was focused
on 159 keV. Planar anterior images were obtained 4 h
(delayed) post-injection (to assess only the active neuronal
tracer uptake) and analyzed using Brain Registration and
Analysis Software Suites (BRASS) (Hermes Medical Solutions;
Stockholm, Sweden). Regions of interest (ROI [counts/voxel])
were placed manually on planar anterior images rectangular in
the upper mediastinum and circular covering the left ventricle
of the heart. Delayed heart to mediastinum ratio (H/M ratio)
was calculated as ROI heart/ROI mediastinum with a site-
specific cut-off value of 1.7. Semi-quantitative BRASS analysis
was supplemented by secondary visual interpretation. Internal
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TABLE 1 | Patient characteristics—epidemiologic distribution, clinical data, and neuroimaging results.
Controls MSA PD p-value
DEMOGRAPHIC DATA
N 8 9 11
Age [Years] 64.8 ± 10.5 61.1 ± 10.8 69.6 ± 8.3 0.302a
Gender [f: m] 3: 5 3: 6 4: 7
BMI [kg/m2] 25.7 ± 4.1 23.0 ± 3.2 25.3 ± 4.7 0.373a
Disease duration [Years] n.a. 5.2 ± 2.6 5.5 ± 4.3 0.867c
UxxRSoff [Points] n.a. 34.3 ± 6.1 24.3 ± 8.9
Follow-up [Months] 41.2 ± 18.8 37.3 ± 23.3 29.1 ± 20.8
AUTONOMIC FUNCTION TESTS
CASScardiovagal [Points] 0.1 ± 0.4 0.8 ± 1.3 0.6 ± 1.0 0.579
a
CASSadrenergic [Points] 0.7 ± 0.5 2.4 ± 1.2
d 1.0 ± 0.0e 0.001a
1SBP [mmHg] 7.1 ± 13.7 −37.4 ± 28.5d −1.6 ± 14.4e 0.001a
ASP [Points] 29.5 ± 26.3 49.0 ± 23.7 21.9 ± 14.8 0.033b
NEUROIMAGING
H/M ratiodelayed n.a. 2.2 ± 0.5 1.7 ± 0.3
f 1.5 ± 0.5d <0.01b,d
SRcontralateralputamen n.a. 2.3 ± 0.3 0.7 ± 0.6
g 0.7 ± 0.4d <0.001a,e
BMI, Body Mass Index; UxxRSoff for PD: UPDRS, Motor Impairment Score part III (off medication); UxxRSoff for MSA: UMSARS, Motor Impairment Score part II (off medication);
CASS, adrenergic/cardiovagal subscore of Composite Autonomic Scoring Scale; 1SBP, Change of systolic blood pressure during head-up tilt; ASP, Autonomic Symptome Profile; H/M
ratiodelayed , heart/mediastinum ratio (4 h post-injection); SRcontralateralputamen, specific binding ratio (contralateral to the clinically more affected side), n.a., not available. p-value < 0.05
was considered to be significant. aKruskal-Wallis Test; bOne-way analysis of variance; cUnpaired, two-tailed t-test. post hoc analysis between groups (Dunn‘s Multiple Comparison Test
and Tukey’s Multiple Comparison Test, respectively): dp < 0.01 vs. ET; ep < 0.05 vs. MSA; fp < 0.05 vs. ET; gp < 0.001 vs. ET.
control was performed by evaluation of control tissue (salivary
gland) and SPECT images.
Autonomic Reflex Screen (ARS)
Cardiovagal and adrenergic function was assessed as heart rate
response to deep breathing and blood pressure response to
Valsalva maneuver and passive head-up tilt, respectively (17)
and scored on the objective Composite Autonomic Scoring
Scale (CASS, cardiovagal, and adrenergic subscores without
sudomotor function) (18).
Statistics
Group data are expressed as mean (standard deviation; SD).
Statistical significance was considered at a p-value < 0.05 (Prism
5.02 for Windows, GraphPad Software, Inc., CA, USA).
RESULTS
Within a 24-month period, we identified 28 patients (10
female, 18 male; mean age 65.5 ± 10.1 years) who underwent
cardiac 123I-MIBG scintigraphy. Clinical indication for nuclear
imaging were suspected Parkinson’s disease (PD, N = 11), MSA
(N = 9), and ET (N = 8) (see Table 1). Mean cardiac 123I-
MIBG H/M ratio (cut-off value 1.7) of both, PD and MSA,
were significantly decreased compared to patients without an
underlying neurodegenerative disorder (ET 2.2 ± 0.5; MSA 1.7
± 0.3; p < 0.05; PD 1.5 ± 0.5; p < 0.01). In this small sample
however, no significance could be revealed between PD and
MSA patients.
Nuclear medical diagnosis deviated from clinically suspected
syndrome in 9 of the 28 cases: cardiac 123I-MIBG binding was
preserved in 3 PD but reduced in 4 MSA and 2 ET patients. To
exclude the potential confounding effect of different reporting
physicians, all 123I-MIBG scintigraphy images were re-evaluated
by an experienced physician blinded for the suspected clinical
diagnosis. Increased mediastinal background activity led to an
adjustment of nuclear medical diagnosis in two cases with indeed
normal myocardial uptake but “pathological” H/M ratio (ET
H/M ratio of 1.58; MSA H/M ratio of 1.65).
The clinical phenotype, long-term follow-up, and results
of additional imaging studies are discussed for the remaining
7 cases with unexpected cardiac 123I-MIBG scintigraphy
results (see Table 2; detailed case description is provided as
Supplementary Materials).
Case 1: 59–62 Years, Possible MSA-P
Clinical Phenotype
Five years of symmetric bradykinesia and rigidity with postural
instability and shuffling gait; startle myoclonus and pyramidal
tract signs (hyperreflexia) within left upper extremity; non-motor:
severe palilalia and dysphagia, urge incontinence, obstipation,
erectile dysfunction, sialorrhea, and mild neurogenic orthostatic
hypotension; UMSARS= 38 pts.
Imaging
cardiac 123I-MIBG scintigraphy:H/M ratio 1.27.
123I-FP-CIT SPECT: visually asymmetric (right) reduced
putaminal tracer uptake.
Discussion
Clinical follow up (rapid progression, early death) strengthened
the initial diagnosis of MSA-P. Medical history and clinical
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TABLE 2 | Summary of pitfalls in cases with an unexpected 123I-MIBG
scintigraphy result.
Unexpected 123I-MIBG results
Pitfall Case Reference
FALSE POSITIVE H/M RATIO
Autonomic Neuropathy/
Ganglionopathy
Ganglionopathy No. 3 (4)
Diabetes mellitus No. 4 (19)
Post-polio syndrome No. 2 (20)
Medication Amiodarone No. 4 (14)
Cardiac rhythm disease Sick-sinus-syndrome No. 4 (21)
FALSE NEGATIVE H/M RATIO
Medication Calcium channel blocker No. 6 (14)
Amiodarone (long-term
administration)
No. 4 (14)
Incorrect diagnosis Progressive Supranuclear
Palsy (PSP)
No. 5
Erroneous position of
mediastinal ROI
Abnormal anatomy
(post-operative/hereditary)
No. 7
H/M ratio, heart/mediastinum ratio; ROI, region of interest.
exam did not reveal clinically significant neuropathy nor
concomitant medication sufficiently explaining reduced cardiac
123I-MIBG uptake.
Case 2: 63–66 Years, Possible MSA-C
Clinical Phenotype
Five years of right sided Parkinsonism (bradykinesia, rigidity),
cerebellar, and pyramidal tract signs; non-motor: apraxia,
dysphagia, obstipation, erectile dysfunction, sialorrhea, and mild
neurogenic orthostatic hypotension; UMSARS= 33 pts.
Imaging
cardiac 123I-MIBG scintigraphy:H/M ratio 1.14.
123I-FP-CIT SPECT: visually symmetric reduced tracer uptake
(putamen, striatum, nucleus caudatus).
Discussion
Clinical diagnosis in this case is less robust as current consensus
diagnostic criteria consider dementia as a non-supporting feature
of MSA. However, MODIMSA study (22) showed evidence
that frontal-executive dysfunction and cognitive impairment is
indeed associated with MSA. Spinocerebellar atrophy (SCA)
causes progressive ataxia, Parkinsonism and pyramidal tract
signs but patients’ familiar history was unremarkable and genetic
screen for SCA 1,2,3, and 6 was negative. Patient had a
history of poliomyelitis during childhood and thus might have
developed post-polio syndrome. However, lower motoneuron
disability in our patient did not progress clinically nor does
electromyography showed signs of active denervation (6-year
follow-up). Autonomic neuropathy has been reported in a case
of post-polio syndrome (20). However, cerebellar symptoms
as well as dementia cannot be explained by the diagnosis of
post-polio syndrome.
Case 3: 59–62 Years, Probable MSA-P
Clinical Phenotype
Two years of symmetric Parkinsonism (bradykinesia, rigidity,
and postural instability), shuffling gait, postural instability,
wheeled walker, impaired fine motor skills; non-motor:
urinary retention requiring catheterization, obstipation,
cold-hand sign, and severe neurogenic orthostatic dysregulation;
UMSARS= 26 pts.
Imaging
cardiac 123I-MIBG scintigraphy:H/M ratio 1.45.
123I-FP-CIT SPECT: asymmetric (right) reduced tracer
uptake (putamen, striatum, nucleus caudatus).
Discussion
Reduction of deep tendon reflexes (ankle) led initially to the
suspicion of axonal motor neuropathy. However, protopathic
sensibility and bathyesthesia were unremarkable, studies of
compound nerve conduction velocity, somatosensible potentials
as well as sympathetic skin response (upper extremities) were
within normal limits. Thus, reduced cardiac 123I-MIBG binding
might be related to clinically insignificant ganglionopathy.
Case 4: 73–76 Years, Essential Tremor
Clinical Phenotype
3.5 year history of action and postural tremor (right >
left), no bradykinesia or rigidity; non-motor: none (including
autonomic history).
Imaging
cardiac 123I-MIBG scintigraphy:H/M ratio 1.49.
123I-FP-CIT SPECT: normal.
Discussion
Patient has a history of type II diabetes that led to distal
symmetric neuropathy (hypopallesthesia, absent ankle deep
tendon reflex) and sick-sinus syndrome. Reduction of cardiac
123I-MIBG binding has been described in both, sick-sinus-
syndrome (21) and diabetic neuropathy (19). However, the effect
of amiodarone is discussed controversially. On the one hand
amiodarone is postulated to reduce 123I-MIBG uptake directly
and on the other hand, through an improved sympathetic tone
due to long-term administration, supposed to increase 123I-
MIBG uptake and block partially 123I-MIBG washout (14). Due
to long half-life amiodarone might not completely washed out
prior to 123I-MIBG scintigraphy.
Case 5: 53–56 Years, Parkinson’s Disease
Clinical Phenotype
Two years of mild asymmetric Parkinsonism (bradykinesia,
rigidity, disturbed finemotor skills), dysarthria, hypomimia; non-
motor: hypersomnia, depressive mood; UPDRS= 18 pts.
Imaging
cardiac 123I-MIBG scintigraphy:H/M ratio 2.08.
123I-FP-CIT SPECT: asymmetric (left) reduced tracer uptake
(striatum, putamen).
Frontiers in Neurology | www.frontiersin.org 4 February 2019 | Volume 10 | Article 152
Skowronek et al. MIBG Scintigraphy in PD and MSA
Discussion
Patients major complain was dysarthria (palilalia) that was
unresponsive to levodopa. Subsequently, the treating neurologist
recommended bilateral subthalamic nucleus stimulation that
was ineffective for dysarthria and all other Parkinson symptoms.
During the 8-year follow-up, patients’ motor symptoms
progressed and he developed supranuclear gaze palsy and severe
postural instability. The patient did not develop autonomic
failure and no frontal-executive dysfunction. Eventually, the
diagnosis of Progressive Supranuclear Palsy (PSP—Parkinson
phenotype, PSP rating scale = 24 pts., PSP staging system = 3)
was established and deep brain stimulation was discontinued.
In this case, cardiac 123I-MIBG scintigraphy correctly pointed
toward non-idiopathic Parkinson’s disease. Clinical phenotype
(Parkinsonism), preserved levodopa response, and absence of
gaze palsy prevented early recognition of PSP.
Case 6: 64–67 Years, Parkinson’s Disease
Clinical Phenotype
Two years history of asymmetric bradykinesia, rigidity and
predominant resting tremor; non-motor: none, ARS without
cardiovagal or adrenergic failure; UPDRS= 24 pts.
Imaging
cardiac 123I-MIBG scintigraphy:H/M ratio 2.11.
123I-FP-CIT SPECT: bilateral reduced tracer uptake
(putamen, striatum, nucleus caudatus).
Discussion
No definite confounder of cardiac MIBG binding could be
identified in this case. Patient’s pharmacotherapy was limited to
calcium channel blocker and rasagiline. Even though, calcium
channel blockers might increase slightly H/M ratio, the extent of
increased H/M ratio is not reasonable (14). Moreover, there is no
evidence for rasagiline altering 123I-MIBG uptake. There were
no clinical signs or symptoms if concomitant neuropathy and no
history of unstable angina pectoris characteristics.
Case 7: 80–83 Years, Parkinson’s Disease
Clinical Phenotype
Four years of asymmetric (left) severe bradykinesia and rigidity,
resting and postural tremor, postural imbalance, camptocormia;
non-motor: none, no evidence of cardiovagal or adrenergic failure
in ARS, no orthostatic hypotension; UPDRS= 29 pts.
Imaging
cardiac 123I-MIBG SPECT:H/M ratio 2.23, corrected to 2.16.
123I-FP-CIT SPECT: asymmetric (left) reduced tracer uptake
(putamen, striatum, nucleus caudatus).
Discussion
Patient had a history of celiac disease and intestinal resection.
Revision of the 123I-MIBG scintigraphy data revealed an
erroneous position of the mediastinal ROI covering relocated
stomach. Despite that correction, 123I-MIBG H/M ratio still lay
within normal limits (2.16).
DISCUSSION
Myocardial 123I-MIBG uptake reflects the density and integrity
of postganglionic sympathetic nerve endings. Due to the
differential involvement of postganglionic sympathetic fibers in
PD but not MSA, reduction of cardiac 123I-MIBG uptake is
used to discriminate both disorders (6). While several studies
(23, 24) propose an association of reduced 123I-MIBGH/M ratio
in PD with longer disease duration, occurrence of non-motor
symptoms and autonomic impairment, others (25, 26) could not
confirm this relationship.
In our clinical series, indication for cardiac 123I-MIBG
examination based on either atypical clinical course or symptom
presentation. As such, our sample represent a highly selected but
in clinical practice common group of patients, as nuclear medical
exams are usually not ordered in clinical obvious cases. Among
these patients, nuclear medical diagnostic classification based
on cardiac 123I-MIBG scintigraphy differed from the clinically
suspected syndrome in one third of cases. Furthermore, group
wise comparison of cardiac 123I-MIBG H/M ratio failed in this
small and selected sample to separate MSA from PD. This is
unexpected considering the high sensitivity and specificity of
cardiac 123I-MIBG scintigraphy to differentiate PD from other
neurodegenerative disorders [pooled specificity range from 77 (8)
to 91% (7)].
The discrepancy between nuclear medical and clinical
diagnosis is explained in part by known confounders of 123I-
MIBG scintigraphy. 123I-MIBG binding is reduced in areas with
impaired sympathetic innervation such as fibrous tissue (e.g.,
myocardial infarction). However, none of our patients showed
focal defects in myocardial 123I-MIBG uptake nor had a history
of unstable angina pectoris characteristics. One PD patient (case
7) suffered from mild coronary heart disease without effect on
H/M ratio. 123I-MIBG uptake is reduced when other compounds
(14) compete for norepinephrine transporter binding at the
presynaptic membrane of postganglionic sympathetic neurons.
Moreover, besides this direct alteration of 123I-MIBG uptake,
amiodarone is discussed to slightly increase 123I-MIBG uptake
through improvement of sympathetic tone (case 4) (14). Cardiac
autonomic neuropathy or ganglionopathy can cause cardiac
sympathetic denervation and thus low 123I-MIBG binding (19).
Despite being clinically unremarkable, ganglionopathy might
underlie H/M ratio reduction in case 3. For a summary of the
possible pitfalls in interpreting 123I-MIBG results, based on our
clinical series, see Table 2.
More recent studies however, confirm our observation
and report patients with unexpected results of cardiac 123I-
MIBG scintigraphy, not sufficiently explained by concomitant
medication or pathology. Nagayama et al. (11) reported on H/M
ratio below the cut-off in 30 out of 96 cardiac 123I-MIBG
examinations performed in 52 MSA patients. Neuropathological
studies further indicate myocardial sympathetic involvement
in MSA, leading probably to a decreased 123I-MIBG uptake.
Orimo et al. revealed reduced TH-immunoreactivity in cardiac
tissue and sympathetic ganglia of 6/15 MSA patients (27).
Moreover, Sone et al. observed phosphorylated α-synuclein
deposits as neuronal cytoplasmic inclusions in sympathetic
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ganglia of 11/26 MSA patients, that could be partially classified
as Lewy bodies (hematoxylin-eosin staining) (28). Cardiac
sympathetic denervation in MSA is unlikely the result of
secondary postganglionic sympathetic degeneration as H/M ratio
shows no temporal trend in repeated 123I-MIBG scans and
H/M ratio does not correlate with clinical severity (11). Cook
et al. (29) reported almost abolished norepinephrine content in
myocardial tissue in an autopsied MSA patient with α-synuclein
deposits limited to glia cells but not in neurons or sympathetic
ganglia. Thus, minor cardiac sympathetic denervation does occur
in MSA. In difference to PD, cardiac sympathetic degeneration in
MSA is limited to TH-immunoreactive sympathetic nerve fibers
(27) and an association with Lewy body pathology is still diversely
discussed (28, 29).
With respect to PD, Orimo et al. (30) reported a pooled
sensitivity of the delayed H/M ratio of 89.7% to detect Lewy
body pathology. However, 123I-MIBG scintigraphy quantifies
cardiac sympathetic denervation that is associated with
Parkinsonism but not the underlying Lewy body pathology.
It is noteworthy that in non-neurodegenerative Parkinsonism
(associated with Parkin, DJ-1, PINK1, and LRRK2 mutations)
cardiac sympathetic impairment is far more heterogeneous and
123I-MIBG scintigraphy remains unremarkably in over 50% of
cases (23). Involvement of cardiac sympathetic fibers has been
reported in early and premotor stages of PD (incidental Lewy
body disease), even before neuronal cell loss and Lewy body
pathology could be detected within the dorsal vagal nucleus and
the nigrostriatal dopaminergic system (5). This may account for
the reduced cardiac 123I-MIBG uptake in early stages of PD as
reported by Umemura et al. (26). In the same study, however, 28
mostly early stage PD patients (15%) had H/M ratios above the
cut-off [1.85 (26)]. In another prospective trial of 70 PD patients
with 2 or more 123I-MIBG exams, mean H/M ratio was reduced
at baseline and declined significantly over a 3-year follow-up
(23). Nevertheless, 28/70 individuals had only mildly reduced or
normal 123I-MIBG H/M ratios at baseline. Finally, Kim et al.
(24) raise the question whether a “normal heart” phenotype of
PD exists. In their study of 160 cases with de-novo PD, 44 had
normal cardiac 123I-MIBG uptake.
In contrast to well-defined and highly selected samples
in prospective trials, we report in our clinical series on the
performance of cardiac 123I-MIBG in a clinical setting. As
such, indication for nuclear imaging was based solely on
individual clinical necessity, which in turn causes a selection
bias toward non-typical symptom presentation and early disease
stages whereas cases with instant clinical diagnosis are neglected.
Among Parkinson patients however, age-dependent metabolic
and vascular conditions are common. We deliberately did not
exclude patients with concomitant conditions (other than history
of unstable angina pectoris characteristics pointing to a probable
myocardial infarction) that potentially involve the CNS or affect
autonomic testing to assess feasibility of cardiac 123I-MIBG
imaging under actual clinical conditions. As neuropathological
confirmation is not available, final diagnostic classification relies
on combined clinical criteria (comprehensive clinical exam,
levodopa responsiveness, and clinical follow-up) of limited
specificity as well.
In summary, cardiac 123I-MIBG scintigraphy is a
highly specific and valuable tool to discriminate Parkinson
syndromes and to access postganglionic autonomic (cardiac)
impairment. 123I-MIBG analysis delivers important insights
in pathophysiological processes and plays a significant role in
scientific approaches and in specific clinical diagnostics in the
broad spectrum of movement disorders and other diseases and
syndromes. Group wise comparisons of delayed H/M ratio
proved repeatedly to be sensitive and specific in detection and
differentiation of PD from other neurodegenerative disorders.
As in other imaging diagnostics, frequent pitfalls and restrictions
have to be recognized and considered in the interpretation
of these findings. We need to emphasize that 123I-MIBG
scintigraphy is usually applied in geriatric patients, an age group
where comorbidities and these pitfalls occur frequently. Thus,
predictability for individual cases and feasibility in routine
clinical practice are diminished. The confounding effects of
concomitant medications, a progressive decline of 123I-MIBG
uptake [∼3%/year (23)] and a growing understanding of the
complex and overlapping pattern of neurodegeneration in
Parkinson syndromes, still requires clinical verification of
the 123I-MIBG scintigraphy results on an individual basis.
In the routine clinical practice, interpretation and drawing
consequences from 123I-MIBG scintigraphy results have to be
done carefully and should be in the hands of very experienced
physicians and movement disorder specialists, respectively.
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